Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
What is your approach to re-challenging patients with immune checkpoint inhibitors whom developed predominately acute tubular injury without acute interstitial nephritis?
Related Questions
Are there any special considerations you take with ESA use in hospitalized patients with ESKD who undergo stem cell transplantation?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Do you postpone hemodialysis for a period of time after stem cell transplantation in a hospitalized patient with ESKD?
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
Would you avoid a 24 hour urine collection for creatinine clearance measurement in a patient who is on fluid restriction?
At what level of renal impairment do you typically reduce or avoid methotrexate in your rheumatology practice?
What is your approach to using intraperitoneal sodium thiosulfate for a patient with ESKD on peritoneal dialysis who develops calciphylaxis?
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
